Page 18 - Pharma Companies

Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs

NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.

Firms' next challenge: Handling staff refusing to take Covid-19 vaccine

Top European biz group with representation from top firms to approach govt for guidelines

Wockhardt, IIL discuss manufacturing tie-up with US vaccine major Moderna

Around November, IIL had indicated that it was open to discussions with the US major.

Three flights carrying coronavirus vaccines land at Delhi airport

Three flights carrying COVID-19 vaccines from Pune and Hyderabad landed at the Delhi airport on Wednesday, its spokesperson said.

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats

Serum Institute may supply around 400 million more doses to Gavi-Covax

Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose

What sets Zydus Cadila apart among indigenous players in Covid vaccine race

The company says the stability of the vaccine is one of its biggest advantages amid dry runs of mass vaccination programmes being conducted in some states

Brexit to benefit Indian firms only in the long run, say analysts

Auto, pharma, IT, chemicals among sectors with significant reliance on UK and European nations with Tata Motors, Motherson Sumi, Tata Steel, TCS, Wipro, Infosys and Tech M among key names

USFDA informs Biocon, Mylan of deferred action on biosimilar license plea

Biocon said its arm, Biocon Biologics, and Mylan have been informed by the USFDA of a deferred action on the biologics license application for a biosimilar to drug Avastin

Centre may not procure Pfizer-BioNTech Covid vaccine over high cost

At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Pfizer working on cold storage issues to ensure temperature integrity

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring.

Pfizer, BioNtech in final stages of talks with WHO to join Covax alliance

The ultra-cold chain requirement of Pfizer's vaccine, unlike most other vaccines, makes it a challenge for most countries including India to store and transport

Singapore-based Everstone buys controlling stake in Calibre for Rs 1,000 cr

Singapore-headquartered, India-focused PE firm Everstone Capital bought a controlling stake in Calibre, a specialty ingredients player focused on pharma, in a reported Rs 1,000-crore deal

UK approves Pfizer, becomes the first country to roll out Covid-19 vaccine

With 800,000 doses expected to be delivered over the next few days, inoculations will begin next week

After e-commerce, CCI looks at pharma sector to unlock competition

Will study the role of trade associations and e-pharmacies in supply chain and whether they're distorting competition

Pfizer vaccine not coming to India soon as trials yet to be conducted

Pfizer has not yet applied for holding clinical trials on Indian volunteers

DRL, RDIF commence clinical trials for Sputnik V Covid-19 vaccine in India

Dr Reddy's Laboratories and Russian Direct Investment Fund (RDIF) on Tuesday said they have commenced adaptive phase 2/3 clinical trials for the Sputnik V COVID-19 vaccine in India. The trials have commenced after receiving the necessary clearance from the Kasauli-based Central Drugs Laboratory, they added. This will be a multicentre and randomised controlled study, which will include safety and immunogenicity study, the Hyderabad-based drug maker and RDIF said in a joint statement. The clinical trials are being conducted by JSS Medical Research as the clinical research partner. Further, Dr Reddy's has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC's clinical trial centres for the vaccine, it added. Recently, RDIF had announced the second interim analysis of clinical trial data, which showed 91.4 per cent efficacy for the vaccine on day 28 after the first dose; and efficacy of o

Moderna vaccine 100% effective in severe cases; to seek US, EU approval

The primary analysis, which included 196 cases, found the vaccine was 94.1 per cent effective, in line with preliminary findings released earlier this month.

Inform people about vaccine in simple language, PM tells manufacturers

Serum Institute in Pune will undertake mass production of Covishield vaccine developed by Oxford-Astra Zeneca